Compare · CALC vs NVO
CALC vs NVO
Side-by-side comparison of CalciMedica Inc. (CALC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CALC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 19975.8x CALC ($9.2M).
- Over the past year, CALC is down 60.7% and NVO is down 33.6% - NVO leads by 27.1 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for CALC).
- Company
- CalciMedica Inc.
- Novo Nordisk A/S
- Price
- $0.59-0.03%
- $41.59+1.01%
- Market cap
- $9.2M
- $183.82B
- 1M return
- -0.59%
- +14.33%
- 1Y return
- -60.72%
- -33.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 6
- 6
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CALC
- SEC Form 4 filed by Bardin Stephen
- SEC Form 4 filed by Leheny A. Rachel
- SEC Form 4 filed by Hebbar Sudarshan
- SEC Form 4 filed by Stauderman Kenneth A.
- SEC Form 4 filed by Dunn Michael J.
- SEC Form 4 filed by Roberts Eric W
- SEC Form 8-K filed by CalciMedica Inc.
- SEC Form EFFECT filed by CalciMedica Inc.
- SEC Form S-3 filed by CalciMedica Inc.
- SEC Form 10-K filed by CalciMedica Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S